GLP1R and metabolic dysfunction-associated steatohepatitis: Although elafibranor seems to be one of the most promising compounds for anti-NASH treatment, a clinical program to evaluate combination therapies with a glucagon-like peptide-1 receptor agonist and a sodium-glucose transporter-2 inhibitor has been recently announced [139].